IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTEGRA LIFESCIENCES HOLDINGS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026
$13.45+0.24 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
INTEGRA LIFESCIENCES HOLDINGS CORP revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Surgery | $1.20B | $1.14B | $1.06B | $1.02B | $1.03B | $894.83M | $996.21M | $963.93M | $720.30M | $632.52M | 73.4% | +5.0% |
| Tissue Technologies | $434.73M | $466.89M | $482.58M | $538.10M | $517.22M | $477.04M | $521.35M | – | – | – | 26.6% | -6.9% |
| Orthopedics and Tissue Technologies | – | – | – | – | – | $477.04M | $521.35M | $508.51M | $467.94M | $359.55M | – | – |
| Specialty Surgical Solutions | – | – | – | – | – | – | – | – | – | $632.52M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Surgery | $120.88M | $504.07M | $450.53M | $417.87M | $439.47M | $356.66M | $395.02M | $363.34M | $292.97M | $256.63M | -76.0% |
| Tissue Technologies | -$31.07M | $139.17M | $134.05M | $233.80M | $228.20M | $159.63M | $144.64M | – | – | – | -122.3% |
| Orthopedics and Tissue Technologies | – | – | – | – | – | $159.63M | $144.64M | $149.51M | $129.70M | $103.85M | – |
| Specialty Surgical Solutions | – | – | – | – | – | – | – | – | – | $256.63M | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.20B | $1.19B | $1.10B | $1.13B | $1.09B | $971.98M | $1.08B | $1.05B | $894.26M | $765.61M | 73.7% | +1.0% |
| Asia Pacific | $189.25M | $176.61M | $193.10M | $176.48M | $182.03M | $157.17M | $157.39M | $144.25M | $80.64M | $59.99M | 11.6% | +7.2% |
| Europe | $162.67M | $158.50M | $165.22M | $170.90M | $191.33M | $172.69M | $197.47M | $201.35M | $150.15M | $120.59M | 9.9% | +2.6% |
| Rest of World | $78.58M | $82.74M | $82.53M | $83.48M | – | – | – | – | – | – | 4.8% | -5.0% |
| Rest of World | – | – | $82.53M | $83.48M | $79.56M | $70.03M | $85.32M | $80.95M | $63.19M | $45.89M | – | – |
From the segment and revenue-disaggregation notes of Integra Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.